Small myeloid subclones are present at diagnosis of multiple myeloma in patients who develop secondary myelodysplastic syndromes von Escure, Guillaume, Fournier, Elise, Saade, Cynthia, Issa, Lama Hasan Bou, Arib, Inès, Tilmont, Rémi, Gazeau, Nicolas, Thiam, Binta M, Chovet, Morgane, Delforge, Maxime, Gower, Nicolas, Fléchon, Léa, Cavalieri, Doriane, Chauvet, Paul, Nudel, Morgane, Goursaud, Laure, Berthon, Céline, Quesnel, Bruno, Facon, Thierry, Preudhomme, Claude, Duployez, Nicolas, Manier, Salomon

Volltext

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL von Gauthier, Jordan, Gazeau, Nicolas, Hirayama, Alexandre V, Hill, Joshua A, Wu, Vicky, Cearley, Aisling, Perkins, Paula, Kirk, Angela, Shadman, Mazyar, Chow, Victor A, Gopal, Ajay K, Hodges Dwinal, Alexandria, Williamson, Staci, Myers, Jessie, Chen, Andy, Nagle, Sarah, Hayes-Lattin, Brandon, Schachter, Levanto, Maloney, David G, Turtle, Cameron J, Sorror, Mohamed L, Maziarz, Richard T

Volltext

Effective anti-BCMA retreatment in multiple myeloma von Gazeau, Nicolas, Beauvais, David, Yakoub-Agha, Ibrahim, Mitra, Suman, Campbell, Timothy B., Facon, Thierry, Manier, Salomon

Volltext

Efficacy and Safety of CAR T-Cell Therapy Using a Fully Human CD19-Targeted Binder in Adults with Relapsed/Refractory B-ALL von Gauthier, Jordan, Gazeau, Nicolas, Fiorenza, Salvatore, Kimble, Erik L., Vinaud Hirayama, Alexandre, Pender, Barbara S., Di, Henna N, Kirchmeier, Delaney R., Shadman, Mazyar, Cassaday, Ryan D., Riddell, Stanley R., Maloney, David G., Turtle, Cameron J.

Volltext

CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Using a Fully Human CD19-Targeted Single Chain Variable Fragment: Results of a First-in-Human Phase I/II Study von Gazeau, Nicolas, Fiorenza, Salvatore, Kimble, Erik L., Vinaud Hirayama, Alexandre, Pender, Barbara S., Di, Henna A., Kirchmeier, Delaney R., Till, Brian G., Shadman, Mazyar, Riddell, Stanley R., Maloney, David G., Turtle, Cameron J., Gauthier, Jordan

Volltext

Safety and efficacy of nivolumab in patients who failed to achieve a complete remission after CD19‐directed CAR T‐cell therapy in diffuse large B cell lymphoma von Gazeau, Nicolas, Mitra, Suman, Nudel, Morgane, Tilmont, Remi, Chauvet, Paul, Srour, Micha, Moreau, Anne‐Sophie, Varlet, Pauline, Alidjinou, Enagnon Kazali, Manier, Salomon, Morschhauser, Franck, Labalette, Myriam, Yakoub‐Agha, Ibrahim, Beauvais, David

Volltext

Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy von Gazeau, Nicolas, Liang, Emily C., Wu, Qian “Vicky”, Voutsinas, Jenna M., Barba, Pere, Iacoboni, Gloria, Kwon, Mi, Ortega, Juan Luis Reguera, López-Corral, Lucía, Hernani, Rafael, Ortiz-Maldonado, Valentín, Martínez-Cibrian, Nuria, Martinez, Antonio Perez, Maziarz, Richard T., Williamson, Staci, Nemecek, Eneida R., Shadman, Mazyar, Cowan, Andrew J., Green, Damian J., Kimble, Erik, Hirayama, Alexandre V., Maloney, David G., Turtle, Cameron J., Gauthier, Jordan

Volltext

Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia von Gazeau, Nicolas, Derrieux, Coralie, Nibourel, Olivier, Berthon, Céline, Grardel, Nathalie, Goursaud, Laure, Boyer, Thomas, Dumezy, Florent, Coiteux, Valérie, Quesnel, Bruno, Preudhomme, Claude, Roche-Lestienne, Catherine, Duployez, Nicolas

Volltext

Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy von Gazeau, Nicolas, Barba, Pere, Iacoboni, Gloria, Kwon, Mi, Bailen, Rebeca, Reguera, Juan Luis, Corral, Lucía López, Hernani, Rafael, Ortiz-Maldonado, Valentín, Perez-Martinez, Antonio, Maziarz, Richard T., Williamson, Staci, Nemecek, Eneida R., Shadman, Mazyar, Coman, Andrew, Green, Damian J., Chow, Victor A., Hirayama, Alexandre V., Maloney, David G., Turtle, Cameron J., Gauthier, Jordan

Volltext

Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression von Fléchon, Léa, Arib, Inès, Dutta, Ankit K, Hasan Bou Issa, Lama, Sklavenitis-Pistofidis, Romanos, Tilmont, Rémi, Stewart, Chip, Dubois, Romain, Poulain, Stéphanie, Copin, Marie-Christine, Javed, Sahir, Nudel, Morgane, Cavalieri, Doriane, Escure, Guillaume, Gower, Nicolas, Chauvet, Paul, Gazeau, Nicolas, Saade, Cynthia, Thiam, Marietou Binta, Ouelkite-Oumouchal, Aïcha, Gaggero, Silvia, Cailliau, Émeline, Faiz, Sarah, Carpentier, Olivier, Duployez, Nicolas, Idziorek, Thierry, Mortier, Laurent, Figeac, Martin, Preudhomme, Claude, Quesnel, Bruno, Mitra, Suman, Morschhauser, Franck, Getz, Gad, Ghobrial, Irene M, Manier, Salomon

Volltext

Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma von Hirayama, Alexandre V, Kimble, Erik L, Wright, Jocelyn H, Fiorenza, Salvatore, Gauthier, Jordan, Voutsinas, Jenna M, Wu, Qian, Yeung, Cecilia C S, Gazeau, Nicolas, Pender, Barbara S, Kirchmeier, Delaney R, Torkelson, Aiko, Chutnik, Abigail N, Cassaday, Ryan D, Chapuis, Aude G, Green, Damian J, Kiem, Hans-Peter, Milano, Filippo, Shadman, Mazyar, Till, Brian G, Riddell, Stanley R, Maloney, David G, Turtle, Cameron J

Volltext

Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression von Fléchon, Léa, Arib, Inès, Dutta, Ankit K., Hasan Bou Issa, Lama, Sklavenitis-Pistofidis, Romanos, Tilmont, Rémi, Stewart, Chip, Dubois, Romain, Poulain, Stéphanie, Copin, Marie-Christine, Javed, Sahir, Nudel, Morgane, Cavalieri, Doriane, Escure, Guillaume, Gower, Nicolas, Chauvet, Paul, Gazeau, Nicolas, Saade, Cynthia, Thiam, Marietou Binta, Ouelkite-Oumouchal, Aïcha, Gaggero, Silvia, Cailliau, Émeline, Faiz, Sarah, Carpentier, Olivier, Duployez, Nicolas, Idziorek, Thierry, Mortier, Laurent, Figeac, Martin, Preudhomme, Claude, Quesnel, Bruno, Mitra, Suman, Morschhauser, Franck, Getz, Gad, Ghobrial, Irene M., Manier, Salomon

Volltext

Phase I Trial of CAR T-Cell Therapy Using a Fully Human CD19-Targeted Binder for Adults with Relapsed/Refractory B-ALL von Gauthier, Jordan, Gazeau, Nicolas, Fiorenza, Salvatore, Kimble, Erik, Hirayama, Alexandre V., Pender, Barbara S., Di, Henna A, Kirchmeier, Delaney R, Shadman, Mazyar, Cassaday, Ryan D., Riddell, Stanley R., Maloney, David G., Turtle, Cameron J.

Volltext

124 - Phase I Trial of CAR T-Cell Therapy Using a Fully Human CD19-Targeted Binder for Adults with Relapsed/Refractory B-ALL von Gauthier, Jordan, Gazeau, Nicolas, Fiorenza, Salvatore, Kimble, Erik, Hirayama, Alexandre V., Pender, Barbara S., Di, Henna A, Kirchmeier, Delaney R, Shadman, Mazyar, Cassaday, Ryan D., Riddell, Stanley R., Maloney, David G., Turtle, Cameron J.

Volltext

Fully Human CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Results of a First-in-Human Phase I/II Study von Gazeau, Nicolas, Fiorenza, Salvatore, Kimble, Erik, Hirayama, Alexandre V., Pender, Barbara S., Di, Henna A, Kirchmeier, Delaney R, Till, Brian G., Shadman, Mazyar, Riddell, Stanley R., Maloney, David G., Turtle, Cameron J., Gauthier, Jordan

Volltext

15 - Fully Human CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Results of a First-in-Human Phase I/II Study von Gazeau, Nicolas, Fiorenza, Salvatore, Kimble, Erik, Hirayama, Alexandre V., Pender, Barbara S., Di, Henna A, Kirchmeier, Delaney R, Till, Brian G., Shadman, Mazyar, Riddell, Stanley R., Maloney, David G., Turtle, Cameron J., Gauthier, Jordan

Volltext

Anakinra for refractory CRS or ICANS after CAR T-cell therapy von Gazeau, Nicolas, Liang, Emily C., Wu, Qian “Vicky”, Voutsinas, Jenna M., Barba, Pere, Iacoboni, Gloria, Kwon, Mi, Ortega, Juan Luis Reguera, Lopez-Corral, Lucia, Hernani, Rafael, Ortiz-Maldonado, Valentín, Martínez-Cibrian, Nuria, Martinez, Antonio Perez, Maziarz, Richard T., Williamson, Staci, Nemecek, Eneida R., Shadman, Mazyar, Cowan, Andrew J., Green, Damian J., Kimble, Erik, Hirayama, Alexandre V., Maloney, David G., Turtle, Cameron J., Gauthier, Jordan

Volltext

228 - Safety and Efficacy Comparison of Two Anakinra Dose Regimens for Refractory CRS or Neurotoxicity after CAR T-Cell Therapy von Gazeau, Nicolas, Barba, Pere, Iacoboni, Gloria, Kwon, Mi, Bailen, Rebeca, Reguera, Juan Luis, López-Corral, Lucía, Hernani, Rafael, Ortiz-Maldonado, Valentin, Pérez-Martínez, Antonio, Maziarz, Richard T, Williamson, Staci, Myers, Jessie, Dwinal, Alexandria Hodges, Nemecek, Eneida R., Shadman, Mazyar, Cowan, Andrew J., Green, Damian J., Chow, Victor A., Hirayama, Alexandre V., Maloney, David G., Turtle, Cameron J., Gauthier, Jordan

Volltext

Safety and Efficacy Comparison of Two Anakinra Dose Regimens for Refractory CRS or Neurotoxicity after CAR T-Cell Therapy von Gazeau, Nicolas, Barba, Pere, Iacoboni, Gloria, Kwon, Mi, Bailen, Rebeca, Reguera, Juan Luis, López-Corral, Lucía, Hernani, Rafael, Ortiz-Maldonado, Valentin, Pérez-Martínez, Antonio, Maziarz, Richard T, Williamson, Staci, Myers, Jessie, Dwinal, Alexandria Hodges, Nemecek, Eneida R., Shadman, Mazyar, Cowan, Andrew J., Green, Damian J., Chow, Victor A., Hirayama, Alexandre V., Maloney, David G., Turtle, Cameron J., Gauthier, Jordan

Volltext

Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia von Gazeau, Nicolas, Derrieux, Coralie, Nibourel, Olivier, Berthon, Céline, Grardel, Nathalie, Goursaud, Laure, Boyer, Thomas, Dumezy, Florent, Coiteux, Valérie, Quesnel, Bruno, Preudhomme, Claude, Roche-Lestienne, Catherine, Duployez, Nicolas

Volltext